DiRECT (Lancet 2018) is the first registered trial to set remission of type 2 diabetes as a primary outcome and to deliver the intervention in routine primary care rather than a research centre. It supplies two things the fabric did not hold: a quantified total-diet-replacement (TDR) protocol with a structured maintenance phase, and a remission-by-weight-loss dose-response — the %-body-weight -> outcome gradient that grounds the weight-loss lever with a magnitude.
Its pathophysiological premise is Taylor’s twin cycle hypothesis — that T2D of limited duration is driven by excess fat in liver and pancreas and is reversible by negative energy balance. Earlier mechanistic work had normalised liver insulin resistance within 7 days and pancreatic function over 8 weeks on a 600-700 kcal/day diet; DiRECT tests whether this is practicable at scale. [EXTRACTED (Lean - DiRECT T2D Remission 2018) Introduction]
The intervention — an energy target, NOT a macronutrient one
The Counterweight-Plus programme, in three phases:
- Total diet replacement: a low-energy formula diet, “825-853 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fibre”, for 3 months (extendable to 5). Note the 59% carbohydrate — this is a high-carbohydrate, low-energy diet, not a low-carbohydrate one.
- Stepped food reintroduction: 2-8 weeks, “about 50% carbohydrate, 35% total fat, and 15% protein”.
- Structured weight-loss maintenance: ongoing monthly visits, behaviour-change methods (including CBT elements), a step-count target.
«All oral antidiabetic and antihypertensive drugs were discontinued on day 1», reintroduced only per protocol if glucose or blood pressure required it. [EXTRACTED (Lean - DiRECT T2D Remission 2018) Procedures]
Population and design: aged 20-65, T2D diagnosed within 6 years, BMI 27-45, not on insulin. Open-label, cluster-randomised at 49 primary-care practices (the practice, not the patient, was the randomisation unit); 149 per group in the ITT population. Co-primary outcomes, analysed hierarchically: “weight loss of 15 kg or more, and remission of diabetes, defined as glycated haemoglobin (HbA1c) of less than 6.5% (<48 mmol/mol) after at least 2 months off all antidiabetic medications, from baseline to 12 months”. [EXTRACTED (Lean - DiRECT T2D Remission 2018) Methods]
The headline result
| Outcome (12 months, ITT) | Intervention | Control | Effect |
|---|---|---|---|
| Weight loss >=15 kg | 36 (24%) | 0 | p<0.0001 |
| Diabetes remission | 68 (46%) | 6 (4%) | OR 19.7 (95% CI 7.8-49.8) |
| Mean weight change | -10.0 kg (SD 8.0) | -1.0 kg (3.7) | adj diff -8.8 kg (-10.3 to -7.3) |
| HbA1c change | -0.9% | +0.1% | adj diff -0.85% (-1.10 to -0.59) |
| QoL (EQ-5D VAS) | +7.2 | -2.9 | adj diff +6.4 (2.5 to 10.3) |
[EXTRACTED (Lean - DiRECT T2D Remission 2018) Results; Table 2]
The 46% remission rate “greatly exceeded” the 22% deemed a-priori clinically important. On medication: at 12 months 73.6% of the intervention group were on zero oral antidiabetic drugs (vs 18.2% of control), and 68% remained off antihypertensives with no rise in mean blood pressure. [EXTRACTED (Lean - DiRECT T2D Remission 2018) Results; Discussion; Table 2]
The jewel — remission scales with weight loss (dose-response)
Pooling both randomised groups, remission rises monotonically with the weight loss maintained at 12 months. “Remission varied with weight loss in the whole study population”:
| Weight change at 12 months | Remission achieved | Rate |
|---|---|---|
| Weight gained | 0 of 76 | 0% |
| 0-5 kg loss | 6 of 89 | 7% |
| 5-10 kg loss | 19 of 56 | 34% |
| 10-15 kg loss | 16 of 28 | 57% |
| >=15 kg loss | 31 of 36 | 86% |
[EXTRACTED (Lean - DiRECT T2D Remission 2018) Results; Findings]
The discussion states the composite the table implies: “86% of participants with at least 15 kg weight loss, and 73% of those with weight loss of 10 kg or more” achieved remission. [EXTRACTED (Lean - DiRECT T2D Remission 2018) Discussion]
Why this is the high-value finding. A monotone gradient from 0% (weight gain) to 86% (>=15 kg), in a within-population comparison, is direct evidence that the amount of weight lost — not the diet’s composition — is the operative variable. It is a cross-group association (not the randomised contrast), so it carries confounding risk (a responder who loses more may differ), but the biological gradient is steep and coherent with the mechanistic twin-cycle work. Read it as name-the-curve: the curve is monotone over the studied range with no visible plateau below 15 kg — every increment of sustained loss buys more remission. Whether it plateaus above 15 kg is unresolved (the top category is open-ended and the mechanism has a floor — remission is bounded at 100%).
The maintenance phase — the structure the fabric lacked
DiRECT is unusual in designing for maintenance “from the outset”. Among engagers, weight fell sharply in TDR then partly regained: -14.5 kg (95% CI 13.4-15.5) during TDR, then +1.0 kg during food reintroduction and +1.9 kg during maintenance — a net ~-11.6 kg trajectory for completers, against the -10.0 kg ITT mean. [EXTRACTED (Lean - DiRECT T2D Remission 2018) Results]
Adherence: “79% completed the intensive total diet replacement phase”; the ~25% “dropout rate” (6 never engaged, 26 withdrew — 15 during TDR, 6 during reintroduction, 5 during maintenance) marks the programme’s non-acceptability ceiling. This is the missing-piece for the NICE TDR recommendation, which names a low-energy TDR but not the reintroduction+maintenance scaffold -> Diets for Weight Loss - What NICE Recommends. (DiRECT’s 825-853 kcal formula sits at the bottom of NICE’s stated 800-1200 kcal band.)
Synthesis — is remission driven by WEIGHT LOSS or by CARBOHYDRATE RESTRICTION?
The fabric holds a low-carbohydrate remission result (Carbohydrate Restriction and Type 2 Diabetes Remission, Goldenberg 2021). DiRECT achieves remission on a 59%-carbohydrate formula diet — so the two routes must be reconciled. Parameter table (op-weave 2a):
| Parameter | DiRECT (Lean 2018) | Goldenberg 2021 (BMJ MA) | Same quantity? |
|---|---|---|---|
| Outcome | remission = HbA1c <6.5%, off antidiabetic meds >=2 months, 12 mo | remission = HbA1c <6.5% (+/- medication, both defs reported), 6/12 mo | ~YES on the med-free definition; Goldenberg’s headline permits meds |
| Intervention | 825-853 kcal TDR formula, 59% carbohydrate | ”<130 g/day or <26%” carbohydrate | NO — opposite on carbohydrate |
| Mechanism claim | weight loss / negative energy balance (twin cycle) | carbohydrate restriction | NO — the contested variable |
| Weight loss | -10.0 kg (ITT), dose-response to remission | MD -3.46 kg at 6 mo, +0.29 kg by 12 mo (regained) | NO — much larger, sustained |
The fourth column is NO on intervention and mechanism — so this is NOT a like-for-like tension to file. It is an F-refinement, and it runs in DiRECT’s favour on the causal question. Both routes produce weight loss; both produce remission. But:
- DiRECT’s within-population dose-response ties remission directly to kilograms lost, irrespective of macronutrient composition — and it does so at 59% carbohydrate, the opposite of a low-carb diet. So carbohydrate restriction is not necessary for remission: it is achieved here without it. (This does not exclude an added glycaemic contribution from carb restriction beyond the weight it produces — that is untested here, insufficient-evidence, not shown absent.)
- Goldenberg’s own data are consistent with weight-mediation, not competing with it: its low-carb remission and weight advantage both attenuate to null by 12 months as weight is regained (weight MD +0.29 kg at 12 mo; 12-mo medication-free remission RD -0.04, NS). A remission effect that decays in step with the weight advantage is consistent with a weight-loss effect delivered via a low-carb route, rather than a carbohydrate effect independent of weight.
The defensible composite: T2D remission (of short-duration disease) is driven by the magnitude
of sustained weight loss; carbohydrate restriction is one lever for achieving that weight loss, with
no evidence it adds a remission effect beyond the weight loss it produces. This refines — does not
contradict — Goldenberg: the low-carb result
is real, but its framing (“low-carb for remission”) is better read as “weight loss for remission,
low-carb being one delivery route”. A person choosing a diet for remission should optimize for the
weight loss they can sustain, by whichever route they will adhere to
(Low-Carbohydrate vs Balanced-Carbohydrate Diets).
[INFERRED (Lean - DiRECT T2D Remission 2018; Goldenberg - Low Carbohydrate Diets T2D Remission 2021) — the two sources' outcomes reconcile via weight-mediation; neither states this joint reading]
DiRECT states the same logic for surgery: “The essential mechanisms behind bariatric surgery are weight loss and decrease in body fat content, rather than any direct surgical effect” — and “The very large weight losses targeted by bariatric surgery are not essential for achievement of remission”. So across three routes (formula diet, low-carb, surgery) the common cause is weight/fat loss, not the route. [EXTRACTED (Lean - DiRECT T2D Remission 2018) Discussion]
Remission is a real benefit weight loss moves — but it is intermediate
DiRECT is a counterweight to the cardiovascular-event null (Does Weight Loss Reduce Cardiovascular Events): where Look AHEAD showed lifestyle weight loss did not cut CV events, DiRECT shows the same lever delivers a patient-important benefit it demonstrably does move — freedom from diabetes and its drugs, plus a measured QoL gain. Weight loss is indicated for the outcomes it moves; remission is squarely one of them.
But remission is an intermediate outcome, not a hard one. HbA1c normalisation is a strong surrogate for microvascular risk, but DiRECT was “not designed or powered to evaluate effects on complications” and remission can relapse. DiRECT itself reaches for the hard-outcome bridge only by citing a Look AHEAD post-hoc: “a 10% weight loss in the first year… was associated with a 21% decrease in occurrence of cardiovascular outcomes” — the same >=10%-responder signal that page holds as reported, not proven -> Does Weight Loss Reduce Cardiovascular Events. [EXTRACTED (Lean - DiRECT T2D Remission 2018) Discussion]
Limits and bias — read honestly
- Open-label, and allocation was visible to participants (cluster design). Baseline balance suggests limited bias, but blinding of a lifestyle programme is impossible.
- Asymmetric medication handling: antidiabetic drugs were stopped in the intervention arm but not control. The trial compares the whole programme vs standard care, so the remission definition (off-meds HbA1c) is favourable to the arm whose meds were deliberately withdrawn — a design choice, disclosed, that inflates the between-arm remission gap relative to a med-matched comparison.
- 12-month horizon; durability is unaddressed here (follow-up planned to >=4 years). Remission of short-duration T2D only — “remission is less likely with longer durations of disease”.
- Near-uniformly white Scottish/Tyneside population; no unqualified transport to e.g. South Asian groups who develop T2D at lower weight.
- The dose-response is a within-population association, not the randomised contrast — responder confounding is possible.
- Adverse events during TDR were common but mild (constipation, cold sensitivity, headache, dizziness); 9 serious AEs in 7 (4.5%) intervention participants, 2 possibly related (biliary colic + abdominal pain, same participant), none causing withdrawal.
- Coherence, not validity (R1): a strong single trial, not proof the effect transports or persists.